Liminatus Pharma, Inc.
LIMN
$0.98
$0.077.39%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 278.65% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -49.38% | -- | -- | -- | |
| Operating Income | 49.38% | -- | -- | -- | |
| Income Before Tax | 52.55% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 52.55% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 52.55% | -- | -- | -- | |
| EBIT | 49.38% | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | 67.11% | -- | -- | -- | |
| Normalized Basic EPS | 26.16% | -- | -- | -- | |
| EPS Diluted | 67.11% | -- | -- | -- | |
| Normalized Diluted EPS | 26.16% | -- | -- | -- | |
| Average Basic Shares Outstanding | 14.39% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 14.39% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |